These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35323356)

  • 21. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
    Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
    Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of the Cancer Drug Funding Process in Canada.
    Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
    Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Examining the association between oncology drug clinical benefit and the time to public reimbursement.
    Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW
    Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario?
    Fontrier AM; Kanavos P
    Value Health; 2023 Jul; 26(7):1011-1021. PubMed ID: 36889379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activities of the pan-Canadian Pharmaceutical Alliance: An Observational Analysis.
    Rocchi A; Mills F
    J Popul Ther Clin Pharmacol; 2018 Aug; 25(2):e12-e22. PubMed ID: 30725539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 27. Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland.
    Wranik WD; Gambold L; Peacock S
    Health Policy; 2021 Mar; 125(3):307-319. PubMed ID: 33388158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
    Yong JH; Beca J; Hoch JS
    Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review.
    Balijepalli C; Gullapalli L; Druyts E; Yan K; Desai K; Barakat S; Locklin J
    Clinicoecon Outcomes Res; 2020; 12():445-457. PubMed ID: 32922050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review.
    Rocchi A; Chabot I; Glennie J
    Clinicoecon Outcomes Res; 2015; 7():287-98. PubMed ID: 26082654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conditional approval of cancer drugs in Canada: accountability and impact on public funding.
    Andersen SK; Penner N; Chambers A; Trudeau ME; Chan KKW; Cheung MC
    Curr Oncol; 2019 Feb; 26(1):e100-e105. PubMed ID: 30853815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost.
    Rawson NS
    Orphanet J Rare Dis; 2017 Mar; 12(1):59. PubMed ID: 28330479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
    Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
    Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Collagen cross-linking using riboflavin and ultraviolet-a for corneal thinning disorders: an evidence-based analysis.
    Pron G; Ieraci L; Kaulback K;
    Ont Health Technol Assess Ser; 2011; 11(5):1-89. PubMed ID: 23074417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?
    Adkins EM; Nicholson L; Floyd D; Ratcliffe M; Chevrou-Severac H
    Clinicoecon Outcomes Res; 2017; 9():327-342. PubMed ID: 28652787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group.
    Garfield S; Polisena J; S Spinner D; Postulka A; Y Lu C; Tiwana SK; Faulkner E; Poulios N; Zah V; Longacre M
    Value Health; 2016; 19(5):577-87. PubMed ID: 27565275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.